跳至主要内容
临床试验/IRCT20151227025726N30
IRCT20151227025726N30尚未招募3 期

Evaluation of the Effectiveness of Two Different Regimens Based on Tosilizumab and Baricitinib in Patients with COVID-19 Respiratory Distress Syndrome

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 100 years(—)
性别
All

入选标准

  • Patients between 18 and 100 years old
  • Laboratory confirmed COVID-19 with RT-PCR
  • Be in severe stage of the disease
  • Have signed the consent to participate in the study

排除标准

  • Acute or chronic renal failure (Increase in creatinine by more than 3.0 in the last 48 hours or GFR less than 30 mL/min)
  • Liver failure (more than 5-fold increase in liver enzymes in asymptomatic patients or more than 3-fold increase in liver enzymes in symptomatic patients or Child Pugh C, D)
  • Hypersensitivity reaction to tocilizumab or baricitinib with severe extravasation and symptoms of anaphylactic shock
  • Mild stage of the disease
  • Pregnant and lactating patients
  • Patients who have been intubated
  • Patients who are expected to die in the next 48 hours

研究者

相似试验

Evaluation of the Effectiveness of Two Different... | 临床试验